Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gibbs

Showing results (301-310 of 427) with videos related to

Pageof 43
Sort By:
Breast Cancer Research and Treatment|January 9, 2023
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancerMatthew Loft, Sheau Wen Lok, Richard De Boer, et al.
Clinical Colorectal Cancer|January 1, 2017
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)Tamás Pinter, Zandra Klippel, Alvydas Cesas, et al.
Molecular Cancer|January 5, 2013
Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletionNeel Sengupta, Christopher Yau, Anuratha Sakthianandeswaren, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2023
Conventional and radiomic features to predict pathology in the preoperative assessment of anterior mediastinal massesMaria Mayoral, Andrew M Pagano, Jose Arimateia Batista Araujo-Filho, et al.
Communications Biology|September 14, 2021
Low-viscosity matrix suspension culture enables scalable analysis of patient-derived organoids and tumoroids from the large intestineYumiko Hirokawa, Jordan Clarke, Michelle Palmieri, et al.
International Journal of Cancer|August 25, 2022
Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA)Sheau Wen Lok, Richard De Boer, Sally Baron-Hay, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 2019
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancerDavid S Williams, Dmitri Mouradov, Clare Browne, et al.
Clinical Colorectal Cancer|July 1, 2018
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International RegistryMatthew Burge, Christine Semira, Belinda Lee, et al.
Breast Cancer Research and Treatment|August 12, 2020
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancerYada Kanjanapan, Sheau Wen Lok, Peter Gibbs, et al.
BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.
Pageof 43

Showing results (301-310 of 427) with videos related to

Sort By:
Pageof 43
Breast Cancer Research and Treatment|January 9, 2023
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancerMatthew Loft, Sheau Wen Lok, Richard De Boer, et al.
Clinical Colorectal Cancer|January 1, 2017
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)Tamás Pinter, Zandra Klippel, Alvydas Cesas, et al.
Molecular Cancer|January 5, 2013
Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletionNeel Sengupta, Christopher Yau, Anuratha Sakthianandeswaren, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2023
Conventional and radiomic features to predict pathology in the preoperative assessment of anterior mediastinal massesMaria Mayoral, Andrew M Pagano, Jose Arimateia Batista Araujo-Filho, et al.
Communications Biology|September 14, 2021
Low-viscosity matrix suspension culture enables scalable analysis of patient-derived organoids and tumoroids from the large intestineYumiko Hirokawa, Jordan Clarke, Michelle Palmieri, et al.
International Journal of Cancer|August 25, 2022
Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA)Sheau Wen Lok, Richard De Boer, Sally Baron-Hay, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 2019
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancerDavid S Williams, Dmitri Mouradov, Clare Browne, et al.
Clinical Colorectal Cancer|July 1, 2018
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International RegistryMatthew Burge, Christine Semira, Belinda Lee, et al.
Breast Cancer Research and Treatment|August 12, 2020
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancerYada Kanjanapan, Sheau Wen Lok, Peter Gibbs, et al.
BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.
Pageof 43